Latest Shareholder Approvals News

Tamboran Resources has successfully closed the first tranche of its PIPE, raising US$38.7 million to advance its Beetaloo Basin projects, with a second tranche pending shareholder approval.

Merchant House International Limited reported a 38% reduction in net loss for FY2025, driven by asset sales and operational wind-down. The company is moving towards divesting remaining assets, delisting from ASX, and winding up.

Wingara AG Limited reported an 18% revenue increase to $3.5 million for FY25 but posted a reduced net loss of $1.47 million, reflecting a strategic pause in fodder operations amid challenging market conditions.

Flagship Minerals has raised A$1.25 million through a share placement and convertible note conversions to advance the Pantanillo Gold Project towards a JORC-compliant resource. The funds will support drilling, metallurgical testing, and environmental studies aimed at unlocking the project’s significant gold inventory.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.

Pacgold Limited has raised $5.6 million through a two-tranche placement to accelerate drilling and exploration at its Alice River Gold Project in North Queensland, signaling strong investor confidence.

American West Metals has launched a $1 million Share Purchase Plan following a $5.9 million placement, offering shareholders a discounted opportunity to invest in its Storm Project exploration activities.

Tennant Minerals has secured $550,000 through a share placement to fund exploration and development at its Barkly copper-gold project, including the promising Bluebird discovery.

Baumart Holdings has completed a modest capital raise through a rights issue, securing $182,303 before costs, with plans to issue additional shortfall shares to bolster its funding position.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.